A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University found
The drug, commonly used to treat epilepsy, calms hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a clinically recognized condition in which memory impairment is greater than expected for a person’s age and which greatly increases risk for Alzheimer’s dementia, according to the study published this week in NeuroImage: Clinical.
The findings validate the Johns Hopkins team’s initial conclusions, published three years ago in the journal Neuron. They also closely match the results in animal studies performed by the team and scientists elsewhere. Next, neuroscientist Michela Gallagher, the lead investigator, hopes the therapy will be tested in a large-scale, longer-term clinical trial.
Hippocampal over-activity is well-documented in patients with aMCI and its occurrence predicts further cognitive decline and progression to Alzheimer’s dementia, Gallagher said.
“What we’ve shown is that very low doses of the atypical antiepileptic levetiracetam reduces this over-activity,” Gallagher said. “At the same time, it improves memory performance on a task that depends on the hippocampus.”
The team studied 84 subjects — 17 of them were normal healthy aged participants and the rest had the symptoms of pre-dementia memory loss defined as aMCI. Everyone was over 55 years old, with an average age of about 70.
The subjects were given varying doses of the drug and also a placebo in a double-blind randomized trial. Researchers found low doses both improved memory performance and normalized the over-activity detected by functional magnetic resonance imaging that measures brain activity during a memory task. The ideal dosing found in this clinical study matched earlier preclinical studies in animal models.
“What we want to discover now, is whether treatment over a longer time will prevent further cognitive decline and delay or stop progression to Alzheimer’s dementia,” Gallagher said.
Read more: Drug Restores Brain Function and Memory in Early Alzheimer’s Disease
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
- Cleveland Clinic receives two grants to study therapeutic potential of anti-cancer drug in Alzheimer'son January 27, 2021 at 3:45 pm
The National Institute of Aging, part of the National Institutes of Health, and the Alzheimer's Drug Discovery Foundation awarded five-year grants of $3.2 million and $1.4 million, respectively, to ...
- Davina McCall on How Menopause Affected Her Memory: 'Please Help Me, I Think I've Got Alzheimer's'on January 27, 2021 at 1:59 pm
Davina McCall has opened up about the impact of menopause on her life in a new interview – including revealing that she was 'paranoid' that she had contracted Alzheimer's diseas ...
- Dementia Tied to Large Perivascular Spaceson January 27, 2021 at 1:00 pm
Enlarged fluid-filled spaces around cerebral small blood vessels were linked to cognitive decline, a prospective study of older adults showed. Severe perivascular space pathology in both the basal ...
- New NIH grant supports research on Alzheimer's disease caused by gene mutationson January 26, 2021 at 5:47 pm
A new grant from the National Institute On Aging at the National Institutes of Health will support ongoing research at Rensselaer Polytechnic Institute to address Alzheimer's disease caused by gene ...
- NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Boardon January 26, 2021 at 5:30 am
NervGen Pharma Corp., a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer's ...
- Serum d-serine levels are altered in early phases of Alzheimer’s disease: towards a precocious biomarkeron January 25, 2021 at 4:00 pm
Alzheimer’s disease (AD), the most common cause of late-onset dementia, is a chronic and progressive neurodegenerative disease affecting ≈6% of adults over 65 years of age 1. The preliminary diagnosis ...
- Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s diseaseon January 25, 2021 at 4:00 pm
Alzheimer’s disease (AD) is the leading cause of dementia, affecting tens of millions of people worldwide 1. Clinically, it is characterized by multifaceted symptoms including both cognitive ...
- First observation of the early association between proteins linked to Alzheimer's diseaseon January 25, 2021 at 10:19 am
During the pre-clinical stages of Alzheimer's disease, i.e. when subtle changes are taking place in the brain but no cognitive symptoms can be observed, the cortex presents a state of transient ...
- Researcher gets $100K for Alzheimer’s disease researchon January 25, 2021 at 3:10 am
Daniel Czyz, Ph.D., assistant professor at the University of Florida, is one of 10 researchers exploring the link between an infectious agent and Alzheimer’s disease who have each been awarded ...
- First observation of the early link between proteins linked to Alzheimer's diseaseon January 24, 2021 at 4:00 pm
Researchers demonstrate, for the first time in humans, how the first deposits of tau proteins in the brainstem are associated with neurophysiological processes specific to the early stages of ...
via Bing News